STOCK TITAN

Avalyn Pharma holder reports four stock sales

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Avalyn Pharma Inc. (AVLN) common stock held indirectly by F-Prime Capital Partners Healthcare Fund V LP was sold in four transactions reported by FMR LLC, a 10% owner. On November 9, 2026, the fund sold 173,661 shares at a weighted-average price of $29.06 and 1,339 shares at a weighted-average price of $29.75; on November 10, it sold 5,565 shares at a weighted-average price of $29.56 and 47,889 shares at a weighted-average price of $30.28. No Rule 10b5-1 plan is reported.

Insider FMR LLC
Role 10% Owner
Sold 228,454 shs ($6.70M)
Share of Position Sold 10.0%
Type Security Shares Price Value
Sale Common Stock F3 5,565 $29.56 $165K
Sale Common Stock F4 47,889 $30.28 $1.45M
Sale Common Stock F1 173,661 $29.06 $5.05M
Sale Common Stock F2 1,339 $29.75 $40K
Holdings After Transaction: Common Stock — 2,056,081 shares (Indirect, F-Prime Capital Partners Healthcare Fund V LP)
Holdings Before and After: Common Stock, 2,284,535 to 2,056,081 shares (Indirect, F-Prime Capital Partners Healthcare Fund V LP)
Footnotes (4)
  1. F1. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.65 to $29.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
  2. F2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.68 to $29.83. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
  3. F3. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.82 to $29.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
  4. F4. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.82 to $30.62. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Shares sold 173,661 shares November 9, 2026 transaction
Weighted-average sale price $29.06 per share November 9, 2026 transaction
Shares sold 1,339 shares November 9, 2026 transaction
Weighted-average sale price $29.75 per share November 9, 2026 transaction
Shares sold 5,565 shares November 10, 2026 transaction
Weighted-average sale price $29.56 per share November 10, 2026 transaction
Shares sold 47,889 shares November 10, 2026 transaction
Weighted-average sale price $30.28 per share November 10, 2026 transaction
weighted average price financial
"The price reported for this transaction is the weighted average price of multiple trades"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVLN shares did F-Prime Capital Partners Healthcare Fund V LP sell, and at what prices?

F-Prime Capital Partners Healthcare Fund V LP sold the reported shares in four transactions: 173,661 shares at a weighted-average price of $29.06 and 1,339 at $29.75 on November 9, 2026; then 5,565 at $29.56 and 47,889 at $30.28 on November 10, 2026. No Rule 10b5-1 plan is reported.

What were the AVLN sale-price ranges underlying the reported averages?

For the November 9, 2026 sales, the ranges were $28.65–$29.64 for 173,661 shares and $29.68–$29.83 for 1,339 shares. For the November 10, 2026 sales, the ranges were $28.82–$29.81 for 5,565 shares and $29.82–$30.62 for 47,889 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FMR LLC

(Last)(First)(Middle)
245 SUMMER STREET

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)XOther (specify below)
See Remark 1
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/09/2026S173,661D$29.06(1)2,110,874IF-Prime Capital Partners Healthcare Fund V LP
Common Stock11/09/2026S1,339D$29.75(2)2,109,535IF-Prime Capital Partners Healthcare Fund V LP
Common Stock11/10/2026S5,565D$29.56(3)2,103,970IF-Prime Capital Partners Healthcare Fund V LP
Common Stock11/10/2026S47,889D$30.28(4)2,056,081IF-Prime Capital Partners Healthcare Fund V LP
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.65 to $29.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.68 to $29.83. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
3. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.82 to $29.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
4. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.82 to $30.62. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Remarks:
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager.
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading